as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹138.48
Change
+0.66 (0.48%)
Open
₹140.0
Prev. Close
₹137.82
Day High
₹144.0
Day Low
₹135.71
Volume Analysis
Traded
179,885
Delivered
70,126
Delivery %
38.98%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Low return on equity (1.59%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (43/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹151.38 | ₹147.69 | ₹143.09 | ₹139.4 | ₹134.8 | ₹131.11 | ₹126.51 |
| Fibonacci | ₹147.69 | ₹144.52 | ₹142.57 | ₹139.4 | ₹136.23 | ₹134.28 | ₹131.11 |
| Camarilla | ₹140.76 | ₹140.0 | ₹139.24 | ₹139.4 | ₹137.72 | ₹136.96 | ₹136.2 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+96.79%
1 Week
+3.61%
1 Month
+10.38%
3 Months
+11.68%
6 Months
+115.1%
1 Year
+89.1%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹36.86
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
1.26%
Net margin 1.01% × asset turnover 0.69x × equity multiplier 1.81x
Company Overview
Sector
Healthcare
Market Cap
₹716 Cr
P/E (TTM)
194.0
ROE
1.59%
Book Value
₹55.4
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 22 Sep 2026. Not investment advice.
TopFund Analysis
Zim Laboratories Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (92/100), while Growth (5/100) is the weakest area to weigh before deciding. Notably: Low return on equity (1.59%); promoter holding is falling.
TopFund Score — Fundamentals Quality
43/100 — WeakData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company's working capital requirements have reduced from 52.8 days to 41.0 days
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 4.03% over past five years.
- −Promoter holding is low: 30.4%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
ZIM Laboratories SpA incorporated in Chile on 9 September 2026 as a wholly owned subsidiary for LATAM expansion.
ZIM FZE completed approved investment in ZIM Scientific Office LLC, retaining 100% holding.
Postal ballot passed on 11 Aug 2026 approving remuneration revisions for MD Dr. Anwar Daud and WTD Mr. Zulfiquar Kamal.
Postal ballot special resolutions passed on 11 Aug 2026 to revise remuneration for MD and WTD.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 67 | 86 | 96 | 118 | 82 | 92 | 96 | 109 | 72 | 89 | 109 | 105 | 94 |
| Expenses + | 63 | 77 | 85 | 102 | 74 | 83 | 85 | 94 | 68 | 83 | 96 | 98 | 92 |
| Operating Profit | 5 | 9 | 12 | 16 | 8 | 10 | 12 | 15 | 4 | 6 | 13 | 7 | 2 |
| OPM % | 7.15% | 10.87% | 11.98% | 13.28% | 9.83% | 10.34% | 12.0% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.6% |
| Other Income + | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 6 | 1 |
| Interest | 2 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 0 | 5 | 7 | 11 | 1 | 3 | 6 | 8 | -2 | 0 | 6 | 5 | -6 |
| Tax % | -22.22% | 23.71% | 31.81% | 26.48% | 27.42% | 19.59% | 30.0% | 39.7% | -22.63% | 23.53% | 27.27% | 24.29% | -28.01% |
| Net Profit + | 0 | 4 | 5 | 8 | 1 | 2 | 4 | 5 | -2 | 0 | 4 | 4 | -4 |
| EPS in Rs | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | -1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 266 | 269 | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 | 397 |
| Expenses + | 278 | 239 | 203 | 238 | 293 | 255 | 268 | 292 | 347 | 326 | 335 | 344 | 369 |
| Operating Profit | -12 | 30 | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 | 28 |
| OPM % | -4.4% | 11.0% | 13.0% | 13.0% | 13.0% | 8.0% | 13.0% | 12.0% | 13.0% | 11.0% | 12.0% | 8.0% | 7.0% |
| Other Income + | 2 | -2 | 5 | 9 | 2 | 5 | -3 | 4 | 6 | 5 | 6 | 11 | 11 |
| Interest | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 7 | 11 | 13 | 14 |
| Depreciation | 7 | 9 | 9 | 10 | 11 | 14 | 16 | 16 | 17 | 16 | 20 | 20 | 20 |
| Profit before tax | -27 | 5 | 18 | 25 | 22 | 0 | 10 | 21 | 35 | 24 | 18 | 8 | 5 |
| Tax % | -19.0% | 5.0% | -6.0% | 23.0% | 30.0% | -4,600.0% | 28.0% | 31.0% | 31.0% | 27.0% | 32.0% | 29.0% | — |
| Net Profit + | -22 | 5 | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 | 4 |
| EPS in Rs | — | — | — | — | 3 | 1 | 2 | 3 | 5 | 4 | 3 | 1 | 1 |
| Dividend Payout % | 0.0% | 16.0% | 4.0% | 4.0% | 5.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 190 | 204 | 243 |
| Borrowings + | 93 | 96 | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 112 | 118 | 127 |
| Other Liabilities + | 78 | 61 | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 96 | 102 | 116 |
| Total Liabilities | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
| Fixed Assets + | 87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 | 162 |
| CWIP | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 70 | 96 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 | 282 |
| Total Assets | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
| Equity Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 | 54 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | — | 22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 | 50 |
| Cash from Investing Activity + | — | -12 | -7 | -26 | -21 | -19 | -6 | -14 | -35 | -73 | -40 | -55 |
| Cash from Financing Activity + | — | -10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | 60 | -9 | 28 |
| Net Cash Flow | — | 0 | 0 | 1 | -1 | 1 | 0 | 2 | 3 | 3 | -8 | 23 |
| CFO/OP | — | 77 | 109 | 117 | 85 | 119 | 83 | 121 | 86 | 46 | 92 | 177 |
| Free Cash Flow | — | 9 | 24 | 8 | 15 | 3 | 25 | 34 | 1 | -57 | 1 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 66.75% | 66.74% | 66.74% | 66.74% | 66.73% | 66.29% | 66.49% | 66.46% | 66.52% | 66.52% | 69.57% | 68.28% |
| Promoters | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 30.35% | 30.36% |
| FII | 0.0% | 0.0% | 0.01% | 0.0% | 0.0% | 0.21% | 0.01% | 0.03% | 0.0% | 0.02% | 0.0% | 0.03% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.24% | 0.24% | 0.24% | 0.24% | 0.2% | 0.07% | 1.34% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Zim Laboratories Limited (this stock) | 716 | 194.0 | 2.42 | 1.59% |
| Valiant Laboratories Ltd | 678 | 42.4 | 2.19 | -1.2% |
| Fabtech Technologies Ltd | 661 | 13.6 | 1.58 | 12.5% |
| Wanbury Limited | 784 | 18.2 | 12.38 | 76.5% |
| Kilitch Drugs India Ltd | 786 | 26.2 | 2.81 | 10.6% |
| Gaudium Ivf N Women H L | 837 | 36.2 | 5.55 | 24.7% |
| Bafna Pharmaceuticals Ltd | 842 | — | 1.65 | -6.18% |
Which Mutual Funds Hold Zim Laboratories Limited?
Frequently Asked Questions about Zim Laboratories Limited
Zim Laboratories Limited (ZIMLAB) closed at ₹138.48 on NSE on 25 September 2026, up 0.66 (0.48%) from the previous close.
Zim Laboratories Limited trades on the NSE (National Stock Exchange of India) under the symbol ZIMLAB.
Zim Laboratories Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 194.0.
Zim Laboratories Limited has a dividend yield of 0.0%.
Zim Laboratories Limited's 52-week high is ₹145.0 and its 52-week low is ₹59.3.
Zim Laboratories Limited has a market capitalisation of ₹716 crore.
Zim Laboratories Limited has a TopFund Quality Score of 43/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Zim Laboratories Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.